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ABSTRACT
Retrocyclin RC-101, a θ-defensin with lectin-like properties, potently inhibits infection
by many HIV-1 subtypes by binding to the heptad repeat (HR)-2 region of gp41 and preventing
six-helix bundle formation. In the present study, we used in silico computational exploration to
identify residues of HR2 that interacted with RC-101 and then analyzed the HIV-1 Sequence
Database at LANL for residue variations in the HR1 and HR2 segments that could plausibly
impart in vivo resistance. Docking RC-101 to gp41 peptides in silico confirmed its strong
preference for HR2 over HR1, and implicated residues crucial for its ability to bind HR2. We
mutagenized these residues in pseudotyped HIV-1 JR.FL reporter viruses, and subjected them to
single round replication assays in the presence of 1.25-10ug/ml RC-101. Except for one mutant
that was partially resistant to RC-101, the other pseudotyped viruses with single-site cationic
mutations in HR2 manifested absent or impaired infectivity or retained wild-type susceptibility
to RC-101. Overall, these data suggest that most mutations capable of rendering HIV-1 resistant
to RC-101 will also exert deleterious effects on the ability of HIV-1 to initiate infections - an
interesting and novel property for a potential topical microbicide.
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CHAPTER ONE: INTRODUCTION
Overview
HIV-1 is a worldwide problem with 4.3 million new infections in 2006 (Joint United
Nations Programme on HIV/AIDS. 2006). The theta-defensin RC-101 prevents HIV-1 infection
(Owen, Rudolph et al. 2004). It is similar in structure and function to other theta-defensins of
lower primate innate immune systems and has shown a remarkable ability to remain effective as
an HIV-1 fusion inhibitor in extended viral culture (Cole, Yang et al. 2006). RC-101’s primary
target is gp41, a glycoprotein on the surface of HIV. A trimer of gp41 molecules forms a 6-helix
bundle that catalyzes the fusion of the host and viral membranes. RC-101 prevents the formation
of the six-helix bundle (Gallo, Wang et al. 2006), putatively through its binding to heptad repeat
2 (HR2) region of gp41. However, the exact mechanism of inhibition is still unclear, and is the
subject of the current study. One-hundred days of serial passaging of HIV-1BaL in the presence
of RC-101 revealed an escape mutant with three cationic mutations in the envelope gene, of
which two were on the heptad repeat regions that comprise the six-helix bundle (Cole, Yang et
al. 2006). To better understand the mechanism of RC-101 mediated viral inhibition, we used an
in silico computational approach complemented with in vitro HIV-1 inhibition studies to
examine the interaction between RC-101 and the two heptad repeats of gp41. Site-directed
mutagenesis was used to test the sensitivity of the virus to cationic mutations along HR2 while
molecular dockings were performed to uncover site-specific interactions and locate residues of
importance for RC-101 binding.
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Innate Immunity
Innate immunity describes a de facto approach to prevent microbial and viral assaults. It
is the first line of defense for all organisms, and for many it is the only defense (Danilova 2006).
Innate immune systems evolved slowly over millions of years; consequently, effectors largely
respond to molecular patterns whereas the adaptive immune system evolves through somatic cell
rearrangement and can target specific epitopes on a pathogen. The innate immune system
manifests itself in a variety of forms that include physical barriers such as skin, and chemical
mediators such as antimicrobial peptides. Pattern recognition receptors recognize molecular
signatures specific to pathogenic microbes and viruses and trigger an immune system response
when activated. In humans, toll-like receptors (TLR) respond to the molecular patterns of
foreign pathogens such as specific sugars, LPS molecules, double-stranded RNA and viral DNA.
TLRs act in reactive fashion to prevent bacterial or viral pathogens from gaining a foothold in
the host cells and the environment (Trinchieri and Sher 2007). The receptors can activate the
release of antimicrobial peptides, activate apoptotic pathways inside the cell and even signal the
adaptive immune system to respond to infection.
Like TLRs, soluble molecular effectors of the innate immune system can also capitalize
on the molecular patterns of bacteria and viruses. For example, lysosyme has been shown to
prevent infections in the ocular region (Bron and Seal 1986) and mucosa of the respiratory
system (Cole, Thapa et al. 2005) by attacking the peptidoglycan moieties in many bacterial cell
walls. Similarly, lactoferrin sequesters iron, a key ingredient for microbial growth, and binds to
the surface of bacteria. It can also modulate the immune response by suppressing inflammation
and signaling the cells of the adaptive immune system to proliferate (Legrand, Elass et al. 2006).
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In response to the innate immune system, viral and bacterial pathogens have evolved a
number of mechanisms to evade or counteract the immune system. Some bacteria maintain
proteases and enzymes that can modify their anionic membranes and therefore reduce the
number of anionic charges on its cell wall or outer membrane. As most antimicrobial peptides
are cationic, this reduced surface charge prevents the peptide’s initial electrostatic interaction
with the microbial membrane. Other bacteria expel the antimicrobial peptides using specialized
protein efflux pumps (Peschel 2002). Yet, many viruses and bacteria remain susceptible to the
effectors of innate immunity because the effectors respond to molecular patterns crucial to the
pathogens’ survival.
Defensins
Defensins are the most widely studied family of antimicrobial peptides and are
characterized by their cationic charge at neutral pH, six cysteines which form three disulfide
bonds, and largely beta-sheet conformations (Lehrer 2004). Defensins exert broad spectrum
antimicrobial and antiviral activity against a range of Gram-positive and Gram-negative bacteria,
fungi, and enveloped and non-enveloped viruses.

In primates, three defensin classes exist

(alpha-, beta- and theta-defensins), which are characterized by their unique tri-disulfide motif.
The molecular structures of the three classes of defensins are rendered in Figure 1.
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Figure 1 Defensins of the Innate Immune System.
The molecules were rendered in the PyMol Molecular Graphics program (DeLano 2002). The
top row of pictures illustrates the secondary structure of each defensins. Beta-sheets are
rendered in yellow and alpha-helices are rendered in red. The bottom row illustrates the charges
on each defensins. Anionic charges are rendered red and cationic charges are rendered in blue.
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Alpha- and Beta-Defensins
While the presence of cationic proteins in granules of leukocyte was discovered in 1966,
elucidating the structure and molecular evolution of these proteins has occurred only recently
(Lehrer and Ganz 2002). The alpha- and beta-defensin classes are the most widely observed
defensins in nature and have been found in a wide range of animals. These two groups of
defensins are thought to have arisen through a common precursor protein because of their
proximity on human chromosome 8 (Liu, Zhao et al. 1997). Overall, there are six types of alphadefensins identified in human. Alpha-defensins 1-4 are expressed by human neutrophils and
participate in the innate immune system throughout the body. Alpha-defensins 5-6 are secreted
by the Paneth cells of the Crypts of Leiberkuhn and play a predominant role in protecting
intestinal mucosa from infection (Cunliffe 2003; Bevins 2005). Beta-defensins are produced
either constitutively or induced in airway, intestinal, liver, and skeletal tissues (Lehrer and Ganz
2002). Beta-defensins are active against a number of bacterial strains and are relatively salt
insensitive (Batoni, Maisetta et al. 2006), thus suggesting a protective role in the physiological
salt concentrations of the mucosa. Both alpha- and beta- defensins are potent against many
bacterial and viral species, but have marginal to moderate activity against HIV-1 (Wang, Owen
et al. 2004; Garzino-Demo 2007). While speculative, this evolutionary oversight may have been
a reason for humans’ susceptibility to HIV.
Theta-Defensins
The third defensin classification, theta-defensin, was the first macro-cyclic protein found
in mammals. Theta-defensin precursor proteins share a great deal of homology with alpha5

defensins, and it is believed that theta-defensins are the result of a duplicated ancestral alphadefensin (Nguyen, Cole et al. 2003). An unknown mechanism splices two precursors together to
create the macrocyclic peptide.

Rhesus theta-defensin-1 (RTD-1) was discovered at sub-

micromolar concentrations in the granules of neutrophils and monocytes of rhesus macaque
(Tang, Yuan et al. 1999). Rhesus macaque have two unique theta-defensin genes that can be
spliced together to make three unique peptides, RTD-1, 2, and 3 (Figure 2) (Leonova, Kokryakov
et al. 2001). The heterodimeric combination of both genes, RTD-1, is the predominant form
expressed in rhesus leukocytes, while the homodimeric forms are observed to a lesser extent
(Tran, Tran et al. 2002).
Since their initial discovery, theta-defensins have been found in Old World monkeys,
orangutans and a lesser ape species (Tang, Yuan et al. 1999; Nguyen, Cole et al. 2003).
Humans, gorillas, Bonobos and chimpanzees retain a remarkably intact θ-defensin gene and
express θ-defensin mRNA in a variety of cells and tissues, yet their lack of protein expression is
owed to a conserved stop codon in the signal sequence that prevents translation (Nguyen, Cole et
al. 2003). Normally, two theta-defensin precursors would be spliced together by a yet-to-bedetermined mechanism to form a macrocyclic peptide, 18 amino acids long (Lehrer and Ganz
2002). Because human theta-defensins genes only exist as expressed pseudogenes in humans,
the peptide was recreated using solid-phase synthesis and termed Retrocyclin (Cole, Hong et al.
2002) (Figure 3). Retrocyclin showed moderate activity against bacteria, but strong activity
against primary isolates and lab-adapted strains of HIV-1 at low micromolar/ high nanomolar
concentrations. Later, an analogue of retrocyclin, RC-101, was engineered to have a single
arginine-to-lysine mutation on one end of the beta-turns and has an even more potent inhibitory
effect against HIV-1 (Figure 3).
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Alterations in the primary sequence can have a drastic effect on the ability of the peptide
to properly function (Figure 2).

For example, a theta-defensin with arginine-to-lysine

substitutions near the disulfide bonds reduced the peptide’s ability to inhibit the HIV-1BaL escape
mutant as compared to RC-101 (Cole, Yang et al. 2006). Additionally, the macrocyclic structure
is important for proper functionality of the peptide. An open form of RTD-1 was considerably
less effective than the circularized RTD-1 even though it formed a similar structure in solution.
It was concluded that the introduction of the N- and C- terminal groups sufficiently altered the
electrostatic landscape to make it less effective against bacteria (Tang, Yuan et al. 1999; Trabi,
Schirra et al. 2001). A 15N solid state NMR study of retrocyclin-2 (RC-100b) revealed its ability
to insert into anionic lipid membranes, while retrocyclin-2 largely remained on the surface of
zwitterionic membranes (Tang, Waring et al. 2006). This result mirrors difference between
bacterial membrane that have high amounts of anionic headgroups and eukaryotic membranes
with zwitterionic lipid headgroups. Obviously, the charge on theta-defensins is important for
functionality, but the role it plays in HIV-1 inhibition is heretofore unknown.
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Figure 2 Theta-Defensins
The rhesus theta-defensins (RTD) are expressed in vivo. Deviations in RTD-2 and RTD-3 from
RTD-1 are shown in red.

RC-100 represents the retrocyclin (RC) based on the human

pseudogene. RC deviations from RC-100 are shown in green. Theta-defensins are cyclic
peptides and composed of 18 amino acids.
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Figure 3 RC-101 and RC-100
The primary macrocyclic structure of RC-100 and RC-101 is illustrated in A. RC-100 contains
and arginine while RC-101 contains a lysine. The biophysical model of RC-101, B, is the same
model used in the docking experiments described below. Color in the biophysical structure
correlates with those in the cartoon in A.
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HIV-1 Epidemic
While developed countries have seen a reduction in new HIV-1 infections due to antiviral
therapeutics and sex education (Shattock and Moore 2003), less industrialized countries
especially those in sub-Saharan Africa have seen the rampant spread of HIV. There are currently
over 45 million individuals infected with HIV worldwide and 25 million of those infected are in
Africa (Joint United Nations Programme on HIV/AIDS. 2006). Highly Active Antiretroviral
Therapy (HAART) is the predominant treatment for infection, and this includes the use of
combinations of reverse transcriptase inhibitors, protease inhibitors, fusion/entry inhibitors, and
integrase inhibitors (Weiss 2003). Only drugs in the first three classifications are routinely used.
At present there is no cure for HIV, only treatments that can delay the onset of AIDS. The crisis
is further exacerbated by the emergence of single- and multi-drug resistant strains. These strains
often occur because of the difficulty of dosage maintenance in a patient, especially when the
drug is in short supply.
There is also need for topically applied microbicides that can prevent the spread of HIV.
In many cultures, promiscuity and the absence of the woman’s control over the sexual practices
of the partner promote the dissemination of HIV. Microbicides, with and without the use of
other “safe sex” practices, are looked to as a way to control the sexual transmission of HIV-1
(Pope and Haase 2003; McGowan 2006). In early studies, the spermicide nonoxynol-9 was
evaluated for its ability to prevent vaginal HIV transmission. Unfortunately, clinical trials were
halted because the damage nonoxynol-9 caused to the vaginal epithelia actually increased the
risk of transmission (Rustomjee and Abdool Karim 2001). Damage to the vaginal epithelia
induced the expression of proinflammatory cytokines and chemokines, which recruit

10

macrophages and dendritic cells, key targets for initial HIV infection. As an alternative to
nonoxynol-9, the theta-defensin RC-101 is currently being considered as a possible microbicide.
RC-101 is a potent anti-HIV peptide that is non-hemolytic for human red blood cells, noncytotoxic against several human cell lines at concentrations reaching 500 µg/ml, and is not
proinflammatory (Cole, Hong et al. 2002; Venkataraman, Cole et al. 2005). In addition, RC-101
remained active in a cervicovaginal construct for over 9 days without damaging the tissue and
could inhibit HIV-1BaL infection in the presence of vaginal fluid (Cole, Herasimtschuk et al.
2007). These collective data build a strong case for the development of RC-101 as a topical
vaginal microbicide.
Mechanism of HIV Infection
Over the past 25 years, considerable effort has gone into understanding the mechanisms
involved in HIV infection. Consequently, much is known of the viral life-cycle and molecular
structures. In the developing world, unprotected sex is the principal route of HIV infection. In
the vaginal or rectal mucosa, HIV comes in contact with Langerhans cells or dendritic cell (DC).
There are several DCs, each with a unique immunological purpose. In particular, monocytederived DCs contain a DC-specific ICAM-2-grabbing nonintegrin (DC-SIGN). The DC-SIGN is
a C-type lectin binding protein that binds to gp120, internalizes the virus, and somehow protects
the virus from degradation (Knipe, Howley et al. 2001). The DC then transports the virus to the
lymph system, where they present the intact virus to the primary host cell, CD4+ T memory cells
(Wu and KewalRamani 2006).
DCs, in general, express more of the chemokine coreceptor CCR5 than CXCR4 –
consequently, R5 (M-tropic) specific HIV viruses, which utilize CCR5 as a coreceptor for entry,
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are the primary transmitted species. Upon sustained infection, a tropism switch to X4 (T-tropic)
strains of HIV-1, which utilize CXCR4 as a co-receptor, occurs in most individuals and plays a
major role in viral progression (Knipe, Howley et al. 2001).
The envelope proteins play a pivotal role in HIV infection. Trimeric gp120 on the
surface of the virion binds to the CD4 receptor and the appropriate co-receptor; gp120 then
disengages gp41 and allows the HR1 region form a homotrimer (Maddon, Molineaux et al. 1987;
Berger, Murphy et al. 1999; Gallo, Puri et al. 2001). Next, the HR2 regions fold into the
hydrophobic grooves created by the trimerizations of HR1 and create the six-helix bundle (Chan,
Fass et al. 1997; Weissenhorn, Dessen et al. 1997). The formation of the six-helix bundle
(Figure 4) promotes and stabilizes pores in the host membrane and fusion of the host and viral
membranes, which in turn, allows viral RNA and proteins to enter the cells (Melikyan,
Markosyan et al. 2000; Markosyan, Cohen et al. 2003). Finally, and most importantly the
surface of gp41 is highly variable. The error-prone reverse transcriptase of HIV-1 produces
different quasispecies of the virus. This results in epitopes that can readily change in order to
evade the adaptive immune system. One amino acid mutation can alter an epitope enough to
prevent antibody mediated viral inhibition (Wei, Decker et al. 2003).
The high level of mutation in HIV underscores the inability of the scientific community
to develop an effective vaccine against the virus. Conserved epitopes on the envelope proteins
are obscured by a glycan shield and other, more variable, residues (Rodriguez-Chavez, Allen et
al. 2006). There are only a handful of human cross-neutralizing monoclonal antibodies, but even
these can become ineffective if the proper mutation arises (Wei, Decker et al. 2003). It remains
to be seen whether any vaccine containing a combination of HIV epitopes and immunogenic
reagents can elicit an immune response robust and strong enough to attenuate HIV.
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Figure 4 Six-Helix Bundle Formation Drives Viral-Host Membrane Fusion
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The Structure of gp41
The structure of gp41 is essential for viral infection, but has eluded biochemists who have
tried to isolate the full peptide in vitro: when unprotected by gp120, gp41 is very sensitive to
proteases. As an alternative, segments have been synthesized that resist degradation and are
stable in solution (Weissenhorn, Dessen et al. 1997). These peptides primarily consist of the
heptad repeat regions of gp41, the stable, fusogenic core of the protein.
Heptad-repeats are a common element throughout nature and characterize the stacking of
amino acids in the alpha-helix confirmation (Figure 5). Every seventh amino acid in an alphahelix roughly aligns with the seventh amino acid above and below and projects out in the same
direction. Each heptamer creates a facet of the alpha-helix, which is important for proper helix
functionality (Figure 6 and Figure 7).
In the case of gp41, different heptamers have different roles in the formation of the sixhelix bundle and cell-host membrane fusion. HR1 shows a strong propensity to form a trimer in
solution (Chan, Fass et al. 1997). Accordingly, heptamers ‘a’ and ‘d’ of HR1 participate in
trimerizations of the peptides. In vivo, this step occurs after gp120 binds to the CD4 receptor
(Gallo, Puri et al. 2001). The heptamers ‘a’ and ‘d’ in HR2 then bind to the hydrophobic pocket
composed of heptamers ‘g’ and ‘e’ in HR1. Heptamers ‘c’, ‘f’, and ‘b’ of HR1 and ‘g’, ‘c’, ‘f’,
‘b’ and ‘e’ of HR2 are expose to the external environment when gp41 is in its post-fusogenic
state, the six-helix bundle (Figure 6).
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Figure 5 Heptamer Designation of Alpha Helix
Panel A illustrates the heptamer pattern. Arrows represent the amino acid backbone. The
heptamer colors in A correlate to the colors on the cartoon in B. B is a rendering of HR1 and
HR2 of gp41 (PDB-ID: 1AIK) (Chan, Fass et al. 1997). Rendering was done in MacPyMOL
(DeLano 2002).
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Figure 6 Illustration of the Heptamer Functionality of the 6-Helix Bundle
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Figure 7 Rendering of the 6-Helix Bundle per Heptamer Functionality
The proteins are based off of the PDB file: 1AIK (Chan, Fass et al. 1997). The two extra dimers
generated to form the 6-Helix Bundle were generated with crystallographic information in the
published file.

Color correlate to the heptamers in Figure 6 Illustration of the Heptamer

Functionality of the 6-Helix Bundle. Rendering was done in MacPyMOL (DeLano 2002).
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HIV-1 and Retrocyclin
Retrocyclin (RC-100) prevents both X4 and R5 HIV-1 replication in CD4+ PBMC cells
and H9 CD4+ T Lymphocytes from infection. It was further determined that RC-100 does not
directly inactive the virus in suspension (Cole, Hong et al. 2002). RC-100 binds gp120 only
when it is glycosylated and binds to the CD4 receptor with lower affinity than gp120-CD4
binding. Retrocyclin is a lectin, and its ability to bind sugar molecules on the surface of proteins
is undoubtedly connected to its ability to prevent HIV infection. In addition, retrocyclin does not
discernibly discriminate between N- and O-linked sugars (Wang, Cole et al. 2003). RC-100 does
not prevent CD4/CCR5/CXCR4-gp120 binding, but seemed to target the virus at a step prior to
entry (Munk, Wei et al. 2003). This is in direct contrast with alpha-defensins that are thought to
hinder HIV at a post entry step (Wang, Owen et al. 2004). The retrocyclin analog, RC-101, is
more active than RC-100 against primary R5 and X4 isolates and a variety of HIV-1 subtypes
(Munk, Wei et al. 2003). It is even active against isolates that show a slight resistance to RC-100
(Owen, Rudolph et al. 2004).
Why are retrocyclins and theta-defensins in general so active against HIV-1? Gallo et al
(2006) confirmed that RC-100 does not interfere with CD4-gp120 binding, although it did bind
to the proteins. Retrocyclin did not crosslink CD4 molecules and therefore did not interfere with
the lateral mobility of CD4 molecules. Instead it was determined through cell-cell fusion assays
that RC-100 bound the ectodomain of gp41, a possibility only in the late stages of viral fusion.
In the cell-cell fusion assays, the transfer of dye from CV-1 cells expressing viral envelope
proteins on the cell surface to SupT1 cells with CD4, CCR5 and CXCR4 on the surface
measured the fusion ability of different envelope proteins. Envelopes from HIV-1IIIB (X4) and
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HIV-1BAL (R5) Env but not HIV-2ROD were inhibited by RC-100. Fusion between CV-1 cells
expressing HIV-2SBL or SIVMAC Env and Sup T1 cells were only slightly inhibited by retrocyclin.
HIV-2 and SIV have a reduced amount of anionic charge on HR2. It is thought that this
difference in charge prevented the proper electrostatic interactions for viral fusion. Furthermore,
RC-100 prevented the formation of the six-helix bundle (6HB) of in vitro synthesized heptad
repeat (HR)1 and HR2 regions of gp41 of HIV-1 (Gallo, Wang et al. 2006). Taken together,
these data support the fusogenic core of gp41 as the crucial target for retrocyclins.
To further explore the interaction between the HIV-1 envelope and retrocyclins, a study
was undertaken in this lab to determine exactly how theta-defensins inhibit HIV-1. During 100
days of serial passaging, the HIV-1 strain BaL evolved three cationic mutations in the presence
of sub-lethal concentrations of RC-101 (Cole, Yang et al. 2006). Of the three mutations, one was
found in gp120 and one each in the HR1 and HR2 regions of gp41, and all three mutations
converted a polar or anionic residue to a cationic residue (Cole, Yang et al. 2006). In addition,
the cationic mutation in HR2 ablated a commonly glycosylated asparagine residue. Loss of
glycosylated residues in gp41 can reduce the fusion ability of the virus, and alter the shape of
discontinuous epitopes (Perrin, Fenouillet et al. 1998; Wang, Song et al. 2005), and thus the
dependence of viral replication on the presence of RC-101 was not surprising. The cationic
mutations and loss of glycosylated residues suggest an attempt by the virus to repel the cationic
lectin, RC-101 (Wang, Cole et al. 2003; Cole, Yang et al. 2006). Our work continues the effort
to determine the exact mechanism of how retrocyclin inhibits HIV fusion, by employing a
combination of life science and computer science approaches.
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Molecular Docking
AutoDock and a docking methodology called Blind Docking (BD) were used to
discriminate between HR1 and HR2 and identify residues of interest on HR2. AutoDock is the
most widely used docking software (Sousa, Fernandes et al. 2006). The application samples
different torsional conformations and locations using a Lamarckian Genetic Algorithm (LGA) to
return the docked molecule that binds best to the macromolecule.
Genetic algorithms borrow the Lamarckian genetic model of genes and phenotype to
solve otherwise computational intensive programming problems.

In short, a population of

variables called the genotype is manipulated by operations similar in concept to those seen in
biological genetics. The genotype is then tested by translating it to a phenotype, where the
fitness of the genotype is measures.

In the LGA the genotype of the ligand molecule is

represented as a string of variables: three variables for location (x, y, z) , four for rotation
(quaternion), and one variable for each rotatable bond (-180º to +180º).

The phenotype for

molecular docking applications is the atomic spatial coordinates. Fitness is measured as the
change in free energy upon binding to the macromolecule and is also referred to as the Final
Docked Energy (FDE). To measure electrostatics, AutoDock uses a derivative of the amber
electrostatic packages that has been optimized for ligand binding measurements. With an LGA,
the fitness of the phenotype can affect the genotype, hence the “Lamarckian” in the name. The
genotype undergoes a number of operations (Figure 8; blue boxes). Testing each ligand in a
population of spatially unique ligands is computationally intensive, therefore, fitness is initially
evaluated using pre-computed electrostatic grids (one grid per atom type) and only a subset of
the population is chosen for the local search algorithm (Figure 8; yellow box). In the local
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search, the spatial and rotational values are manipulated in a stepwise manner according to the
energy gradient. Each move is tested for increased fitness. The new ligand values are then
reincorporated into the genotype and the best ligand gets passed onto the next generation. When
the exit requirements (Figure 8; magenta diamond) are met, the coordinates of the fittest ligand
found to that point are saved. This whole process is then repeated to create a set of docked
ligands (Morris, Goodsell et al. 1998).
There have been several blind docking studies done (Hetenyi and van der Spoel 2002;
Hetenyi and van der Spoel 2006), and some even included gp41 (Jun Tan, Kong et al. 2005);
however, all have used small molecules as their ligand. Using a highly flexible ligand such as
RC-101 increased the computational complexity; therefore a full exploration of possible ligand
conformations was not as feasible. Therefore, a unique approach was taken to analyze the
collection of fit ligands.

The intermolecular interactions were quantified (McDonald and

Thornton 1994; Wallace, Laskowski et al. 1995) and residues of frequent interaction were
targeted for mutagenesis. Furthermore, the fact that theta-defensins contain a large number of
rotatable bonds supports the notion that more than one bound ligand conformation is possible.
This flexibility along with their amphipathic nature allows them to recognize patterns over
specific epitopes.
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Figure 8 The Lamarckian Genetic Algorithm
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CHAPTER TWO: MATERIALS AND METHODS
Computational Analysis of the Variation in HR1 and HR2
The aligned envelope protein sequences of 913 unique HIV-1 group M viruses were
obtained from the HIV Sequence Database at the Los Alamos National Laboratories (LANL;
www.hiv.lanl.gov), which has been curated by LANL scientific staff for duplicate sequences
from the same source. HIV-1 Group M represents a group of viral isolates that diverged in
humans and originated from one chimpanzee-to-human transmission event, and is the most
common group found in humans (Robertson, Anderson et al. 2000). The amino acid diversity
20
⎛ 20 ⎞ 2
Daa = ⎜∑ x i ⎟ − ∑ x i2
i=1
⎝ i=1 ⎠
, where x is the proportion of the ith amino
index was calculated as

acid of the twenty standard amino acids at that location (Yamaguchi-Kabata and Gojobori 2000).
The value is similar to gene diversity in population genetics (Nei 1987). An amino acid with a
diversity index that is less than .05 is considered monomorphic (Yamaguchi-Kabata and
Gojobori 2000). The residues corresponding to HR1 and HR2 were spliced out of the sequence
file and used for evaluation in the ExPASy pI/Mw tool to determine the isoelectric point
(Bjellqvist, Hughes et al. 1993; Bjellqvist, Basse et al. 1994; Wilkins, Gasteiger et al. 1999).
Preparation of HR1, HR2 and RC-Structure Models
Three

separate

structural

representations

were

needed

for

bio-computational

experimentation: the HR1 and HR2 regions of JR.FL and the θ-defensin RC-101. In the context
of computational data, the HR1/HR2 nomenclature refers only to the N36 and C34 peptides,
respectively. The three-dimensional structural models of the HR1 and HR2 regions of JR.FL
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were generated using Swiss-Model protein homology web server from the HIV-1 gp41 core
structure (PDB-ID: 1AIK) published previously (Chan, Fass et al. 1997; Schwede, Kopp et al.
2003; Arnold, Bordoli et al. 2006). The structure for RC-101 was created with the mutagenesis
function of the PyMOL Molecular Graphics System, based on the structure of retrocyclin-2
(PDB-ID: 2ATG). Two in silico mutations were performed to create RC-101: the second
arginine to a glycine and the fourth arginine to a lysine (Owen, Rudolph et al. 2004). The
backbone atoms for both mutated residues remained stationary. There was no need to minimize
the rotational bond energy of the mutated bonds, since all carbon-carbon or carbon-nitrogen
bonds were deemed “rotatable” in the docking procedure.
Computational Modeling of RC-101 Binding
Grid and Docking parameter files for all RC-101 dockings to dimer and comparative
monomer macromolecules were prepared with AutoDockTools (ADT) and accompanying
scripts, then run with AutoDock 3.0 and AutoGrid 3.0 (Goodsell, Morris et al. 1996; Morris,
Goodsell et al. 1998). The grid parameters were the same for all three macromolecules. The
number of points in the x, y and z direction was 76, 76, and 126 respectively. The grid spacing
value was 0.452777777778 Å.

Finally, the grid center was defined as the xyz-coordinate

(17.449, 13.8, 5.67). All other AutoGrid parameters remained at their default values. The
ligand, RC-101, was prepared with ADT according to the AutoDock Manual (Morris, Goodsell
et al. 1998). For each macromolecule (HR1, HR2, HR1+HR2) and ligand (RC-101), hydrogen
positions were reassigned, non-polar hydrogens were merged, and Kollman United Charges were
assigned to each residue.
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The genetic algorithm variables of population size (200), maximum number of energy
evaluations (2x106), and the maximum number of generations (2x105) were increased from their
default values using Hetenyi et al. as a general guideline (Hetenyi and van der Spoel 2002).
Lower values were used because the protein model contained substantially less solvent-exposed
surface area and contained less than half the average number of residues tested in previous blinddocking studies (Debnath, Radigan et al. 1999; Hetenyi and van der Spoel 2002; Kong, Tan et al.
2006). For each docking simulation the genetic algorithm was run 200 times. Each docking
simulation was executed four times, and the quantitative measures of all four docking
simulations were averaged and the SEM calculated.
Defining Hydrogen and Non-Hydrogen Bonds
Tabulation of hydrogen bonds and non-hydrogen bonds were generated using LIGPLOT
in conjunction with HBPLUS (McDonald and Thornton 1994; Wallace, Laskowski et al. 1995).
The best 25% (50) docked RC-101 molecules, according to the Final Docked Energy, were
tabulated, and the average bonds per residue for four independent docking executions were
reported along with the SEM. See appendix B for more information on the computer code used
in this work.
Preparation of Peptide
The 18 amino acid peptide RC-101 was synthesized as previously described (Tang, Yuan
et al. 1999; Leonova, Kokryakov et al. 2001; Cole, Hong et al. 2002) with the sequence: cyclicGICRC ICGKG ICRCI CGR. After each step the peptide was subjected to MALDI-TOF mass
spectrometry to assess homogeneity (typically ~95%) and to confirm that the observed mass
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agreed with the theoretical mass.

Peptide concentrations were determined by quantitative

peptide analysis.
Cell Culture
HOS-CD4-CCR5 cells (Dr. N. Landau, Salk Institute for Biological Studies, La Jolla,
CA) that allow entry of R5 HIV-1, were acquired from the NIH AIDS Research and Reference
Reagent Program.

HOS cells were grown in DMEM supplemented with penicillin,

streptomycin, 10% FBS, 1 μg/ml puromycin, and mycophenolic acid selection medium. 293T
cells were grown in DMEM with penicillin, streptomycin, and 10% FBS.
HIV-1 Plasmid Constructs and Viral Entry Assay
The expression vectors pNL-LucR–E– and JR.FL env were gifts from Dr. N. R. Landau
(The Salk Institute for Biological Studies, La Jolla, CA). JR.FL is an R5 strain of HIV-1. In
total, 18 JR.FL env mutants were constructed. Nine glutamic acids on the HR2 of HIV-1 gp41
were mutated to lysines. Amino acids 632, 634, 641, 647, 648, 654, 657, and 659 were mutated
from Glu (GAA) to Lys (AAA). Amino acid 636 was mutated from Asp (GAC) to Arg (CGC).
For the second set of mutagenesis studies, polar or hydrophobic residues were mutated to an
arginine or lysine: 638 Tyr (TAC) to Arg (CGC), 640 Ser (AGC) to Arg (AGG), 642 Ile (ATA)
to Lys (AAA), 645 Leu (CTA) to Arg (CGA), 649 Ser (TCG) to Lys (CGC), 651 Asn (AAC) to
Lys (AAA), 653 Gln (CAA) to Lys (AAA), and 656 Asn (AAT) to Lys (AAA).
Each mutation was created from the wildtype JR.FL env plasmid using the QuikChange
Multi Site-Directed Mutagenesis Kit (Stratagene), verified by sequencing (University of Central
Florida Biomolecular Science Center Genomics Core Laboratory, Orlando, FL) and compared to
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the published JR.FL wild-type sequence (Accession Number: U63632). Subsequently, HIV-1
single-cycle (replication incompetent) luciferase reporter viruses were produced by
cotransfecting 293T cells with 10 µg each of pNL-LucR–E– and one of the JR.FL env clones.
Virus-containing, clarified supernatants were collected after 48 hrs, filtered though a .45-µm
filter and stored at -80°C in aliquots until needed. One aliquot was used to quantify propagated
pseudovirus by p24 ELISA (PerkinElmer). Another aliquot was used to ensure the integrity of
the envelope gene. In summary, viral RNA was isolated from the JR.FL pseudotypes (QIAGEN
Viral RNA Mini Kit). A cDNA library was created from the isolated viral RNA with the iScript
Select cDNA Synthesis Kit (BioRad). Then a 666bp envelope region containing HR1 and HR2
was PCR-amplified and detected using a 1.5% agarose gel. The sense primer used was 5’CTGTGTTCCTTGGGTTCTTGG-3’

and

the

antisense

primer

used

was

5’-

CTCCACCTTCTTCTTCGATTCC-3’. To measure infectious ability of JR.FL pseudotypes,
HOS-CD4-CCR5 cells (5 x 103/well; 96-well plate) were infected with 50 ng p24/well of virus in
the presence or the absence of RC-101 (0, 1.25, 2.5, 5, 10 µg/mL), and luciferase activity was
measured 2 days later. The whole process is illustrated in Figure 9.
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Figure 9 Pseudotype Methodology
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CHAPTER THREE: RESULTS
Amino Acid Variation of HR1 and HR2
In order to measure the susceptibility of the envelope gene to mutation and identify viable
escape mutants, we analyzed over 900 HIV-1 Group M envelope protein sequences from the
HIV Sequence Database at LANL. The amino acid diversity of HR1 and HR2 are distinctly
dissimilar (Figure 10A). The majority of sites (28 of 36) on HR1 are monomorphic and do not
readily change, whereas the majority of sites (21 of 34) on HR2 are highly pliable and change
readily between viral strains. Of the eight non-monomorphic sites found on HR1, six are
externally exposed to the environment in the 6HB conformation. To visualize the sequence
variation as a function of biochemical structure we mapped the amino acid diversity values to the
3-dimensional model of HR2 (Figure 10B). The externally exposed regions of HR2 in the 6HB
show a high amount of amino acid diversity, while the HR1 binding domain on HR2 is
predominantly monomorphic. Yamaguchi-Kabata et al. (Yamaguchi-Kabata and Gojobori 2000)
found that discontinuous epitopes in the α-helices of gp120 were under putative positive
selection.

By contrast, the monomorphic sites of HR2 suggest a region under very little

selection. Alternatively, the regions exposed in the 6HB conformation are under strong putative
positive selection from pressure generated by the immune system’s ability to easily access these
exposed epitopes.

RC-101’s long term potency against HIV-1 BaL could be attributed to

interaction with discontinuous epitopes of the monomorphic residues of HR2.
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Figure 10 Amino Acid Diversity of HR1 and HR2
A, the amino acid diversity index of HR1 and HR2 was calculated for 913 group M HIV-1
viruses. All points below the dotted line (.05) are considered monomorphic. B, the diversity
index was mapped to the 3-dimensional structure of HR2 (N-terminal on top).

The

monomorphic residues, more red in color, are found in the HR1 binding region of HR2. The
highly diverse residues, more white in color, are exposed to the external environment in the 6HB
confirmation. The image in B was rendered with MacPyMOL (DeLano 2002).
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Figure 11 Isoelectric Point of HR1 vs. HR2 of Group M HIV-1 Sequences
The isoelectric points of the HR1 and HR2 were obtained by inputting the Group M sequences
into the pI/MW tool of ExPASy.
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Because all three known non-synonymous, RC-101-evasive mutations were cationic
residues (Cole, Yang et al. 2006), we chose to measure the isoelectric points of the heptad repeat
regions of all Group M sequences as a marker of charge diversity. The isoelectric points of the
heptad repeats illustrate ability of HIV-1 to alter its regional charge in vivo. While the amino
acid diversity of HR2 is highly variable, its isoelectric range is acidic and significantly restricted
– 96% of the isoelectric points range between 3.89 and 4.66. Alternatively, HR1 is highly
monomorphic but covers a wide range of isoelectric points (Figure 11). In line with having only
eight non-monomorphic sites, the isoelectric points show a strong inclination to cluster around
certain values: 8.49 (n=30), 9.99 (n=52), 10.29 (n=33), 10.83 (n=569), 11 (n=140), 11.71 (n=58),
and 12.01 (n=12). Sequences with higher HR1 isoelectric points have a greater number of
cationic mutations with fewer anionic residues; the converse is true for HR1 sequences with
more acidic isoelectric points.

The isoelectric range of HR1 is over twice that of HR2,

suggesting a greater in vivo variation in electrostatic density.
RC-101’s Preference for Anionic Charge
While charge interaction plays an important role in RC-101 viral inhibition, it is unknown which
residues play an important role in binding. Because RC-101 still binds gp41 in the absence of
linked sugar molecules, we can reasonably exclude the sugar moieties from having a direct
interaction with RC-101 (Cole, Yang et al. 2006; Gallo, Wang et al. 2006). The molecular
docking program AutoDock (Goodsell, Morris et al. 1996; Morris, Goodsell et al. 1998) was
used to determine RC-101’s affinity for HR1, HR2 and the dimer (HR1+HR2).

Previous

docking procedures to the protein models of HR1 and HR2 focused on docking small molecules
to the helices (Jun Tan, Kong et al. 2005). In contrast, RC-101 contains a large number of
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flexible side chains and flexible side groups. Consequently, our dockings did not elucidate just
one docked residue that can be considered the principal docking site of RC-101, but a number of
RC-101 binding conformations. Four in silico docking experiments revealed a significantly
lower ΔG for RC-101 upon binding HR2 than HR1 (P = .0005). The docking of RC-101 to HR1
alone did not result in a strong binding energy (Figure 12). Conversely, the minimum energy of
binding to HR2 is predominantly lower than values of small molecule inhibitors previously
docked to this model (Jun Tan, Kong et al. 2005) (Figure 12).
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Figure 12 Final Docked Energy of RC-101 Dockings to HR1, HR2, and HR1-HR2 Dimer
Four in silico docking experiments revealed a significantly lower ΔG for RC-101 upon binding
HR2 than HR1 (P = .0005). The ΔG upon binding is also referred to as the Final Docked Energy
(FDE). Error bars represent the SEM.
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Anionic-to-Cationic Mutations on HR2
We created HIV-1 env molecular clones to identify mutations that would effectively alter
HIV-1 susceptibility to RC-101. An expression vector containing env from JR.FL, an R5
pseudotype, was subjected to site-directed mutagenesis to create mutant clones (Figure 9).
Because RC-101 viral entry inhibition is glycan-independent and charge alteration is a common
mechanism of microbial evasion of antimicrobial peptides (Peschel 2002; Lehrer 2004; Cole,
Yang et al. 2006; Gallo, Wang et al. 2006), we individually mutated each negatively charged
amino acid to a positively charged lysine or arginine Figure 13.
After alteration of the env gene, the wild type stock (non-mutated) or mutant JR.FL env
clones were then used to create pseudotyped single-cycle HIV-1 luciferase reporter viruses, and
RC-101 activity against each viral clone was measured. Of the ten JR.FL variants, five variants
showed scant ability to infect HOS.CD4.CCR5 cells (Figure 14A). The mutation on all five lowor non-infectious variants was located on the region of HR2 externally exposed in the 6HB
conformation (heptamers b, c, e, f, and g). Of the five pseudotyped variants that effectively
entered HOS.CD4.CCR5 cells, only the pseudotype with a lysine at amino acid position 648
showed a significant amount of partial resistance to RC-101 (P = .05) (Figure 14B, Figure 15).
Residue 648, part of the ‘g’ heptamer, is located in the central region of the helix and through our
modeling simulations is a potential binding site for the positive residues on RC-101. These data
suggest that the ability of the virus to form the 6HB was significantly decreased and/or the
mutants lost the ability to properly form the gp41 pre-fusion complex. Furthermore, certain
anionic charges on HR2 were integral for proper 6HB formation and did not tolerate cationic
mutations.
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Figure 13 Anionic-to-Cationic Mutations
The top alpha-helix is HR2 of the gp41 molecule. Only the charged residues side chains are
displayed as sticks and labeled. Cationic residues are white, while anionic residues are in black.
Hept. = heptamer location (a-g).
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Figure 14 Relative Light Units of JR.FL Pseudotypes with Anionic-to-Cationic Mutations
The JR.FL env molecular clone was mutated using site-directed mutagenesis according to the
HR2 sequences in Figure 13. Pseudotyped viruses were then used to infect HOS-CD4-CCR5
cells. A shows pseudotypes that infected HOS cell very little or not at all with no RC-101. In
contrast, B shows pseudotypes that infected in a manner similar to the wild-type JR.FL
molecular clone. Error bars represent the SEM (n=4).
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Figure 15 Percent Inhibition of Infectious Anionic-to-Cationic JR.FL Pseudotypes
Percent inhibition was calculated for normal infectious virus, Figure 14B. All the pseudotypes
were inhibited similar to wild type, except for E648K (P = .05). Error bars represent the SEM
(n=4).
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RC-101 Binds to the HR1-binding regions of HR2
Figure 16 shows a rendering of the top 5 docked positions from a representative
AutoDock experiment. Ligands binding to HR1 were non-specific as evidenced by the highly
dispersed RC-101 molecules. In contrast, RC-101 repeatedly bound to HR2 in the same region.
When examining a helical representation of HR2 (Figure 5), the backbone of RC-101 covers the
‘a’ and ‘d’ heptamers, while the long, flexible sidechains of RC-101 extend out and interact with
heptamer locations ‘g’ and ‘e’. Interestingly, these heptamer positions are areas of low amino
acid diversity (Figure 10) that coincide with the region that binds HR1 upon 6HB formation.
RC-101’s strong affinity for HR2 would prevent the interaction of HR1 and HR2, the formation
of the 6HB, and the subsequent fusion of the host and viral membranes (Figure 7), which is
supported by recent in vitro studies (Cole, Yang et al. 2006; Gallo, Wang et al. 2006).
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Figure 16 RC-101 Docks to HR2 in a Site Specific Manner.
The top 5 docked RC-101 molecules of a representative docking, as measured by the FDE, are
shown as silver loops near the α-helix that it was docked to. The RC-101 molecules docked to
HR1 are much more dispersed than the RC-101 molecules docked to HR2. The color of each
residue of HR1 and HR2 correlates with the heptamer designation shown in Figure 5. The
images were rendered in MacPyMOL (DeLano 2002).
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RC-101 Binds Anionic, Polar, and Hydrophobic Residues of HR2
The computer programs LIGPLOT and HBPLUS were used to identify specific
interactions between the ligand, RC-101, and HR2 based on proximity and atomic angles. We
quantified the number of interactions per HR2 residue for the lowest (best) 25% of docked RC101 molecules based on final docked energy for each docking experiment of 200 iterations of the
Lamarckian Genetic Algorithms (Figure 17). The applications identified two sets of molecular
interactions between RC-101 and HR2: hydrogen bonds at residues Serine-649, Glutamine-653
and Asparagine-656 and hydrophobic or non-hydrogen bonded contacts at residues Tyrosine638, Isoleucine-642 and Leucine-645 (Figure 17, asterisks). All six residues are located in the
‘a’ and ‘d’ heptamer regions of HR2, which bind HR1 upon 6HB formation; four of the residues
are monomorphic and the remaining two residues have reasonably low amino acid diversity
values. AutoDock consistently bound RC-101 to a location with low amino acid diversity and
that has an important role in 6HB formation.

41

Figure 17 RC-101 Interaction per HR2 Residues
Four docking experiments were completed, each with 200 Lamarckian Genetic Algorithm. The
best 25% (50) docked RC-101 molecules from each docking experiment were analyzed for
intermolecular interactions (hydrogen bonding and hydrophobic contacts) and tabulated per HR2
residue. Asterisks indicate the six residues of HR2 that had the greatest number of interactions
with RC-101, and which were subjected to in vitro infection assays (Figure 6). Error bars
represent the SEM.
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Cationic Mutations in the HR1-Binding Domain of HR2
Based on the above mentioned study, we created mutant pseudotyped JR.FL env that
contained a cationic mutation at each of the six residues observed to interact with RC-101 in
silico. In addition, we mutated two residues on the 6HB-exposed portion of HR2 (heptamers f
and c) as negative controls (Figure 18):

both of these control pseudotypes infected

HOS.CD4.CCR5 cells and remained sensitive to RC-101. Four mutants were non-infectious
even in the absence of RC-101 (Figure 18B). All non-infectious JR.FL mutants were located on
heptamers that indirectly or directly interacted with HR1 (Figure 18C, Figure 18D) (Chan, Fass
et al. 1997; Suntoke and Chan 2005). Of the JR.FL mutants that did infect HOS.CD4.CCR5
cells, none were resistant to RC-101.
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Figure 18 HR1-Binding Region Mutations of HR2
The JR.FL env molecular clone was mutated using site-directed mutagenesis according to the
HR2 sequences in A. The top alpha-helix is HR2 of the gp41 molecule. Only the charged
residues side chains are displayed as sticks and labeled as in Figure 13. Hept. = heptamer
location (a-g). Pseudotyped viruses were then used to infect HOS-CD4-CCR5 cells. B, cationic
mutations of RC-101-interacting residues revealed non-viable mutations, B, or normally
inhibited mutant pseudotypes, C. All normal infectious mutants were inhibited similar to the
wild-type, C. Error bars represent the SEM (n=4).
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CHAPTER FOUR: DISCUSSION
The envelope protein of HIV-1 is under many kinetic restraints for proper functionality.
First, the short time between gp120-CD4 interaction and 6HB formations limits the time 6HBinhibitors have to act (Gallo, Puri et al. 2001; Dimitrov, Louis et al. 2005). The strong net
negative charge of HR2 and net positive charge of RC-101 creates a strong electrostatic
attraction that likely promotes binding. This is evident in the marked difference observed
between non-specific binding of RC-101 to HR1 and specific binding to HR2 seen in this work.
RC-101 binds reversibly but with high affinity to glycoproteins and associates with the cellular
lipids and proteins involved in host-viral fusion (Wang, Cole et al. 2003; Buffy, McCormick et
al. 2004). This lectin-like binding places RC-101 in a most opportune location to affect 6HB
formation.
As a response to opposing host and environmental factors, HIV-1 employs a number of
counter-measures including a “glycan shield” and the expediated rate of evolution due to the
error-prone nature of its reverse transcriptase protein. Alterations in the glycan shield affects
access to binding sites (Wei, Decker et al. 2003). In addition, the 6HB formed in solution with
the synthetic N36 and a glycosylated C34 peptide was less compact than its non-glycosylated
counterpart (Wang, Song et al. 2005). This suggests a variation in the inter-helical distance and
a possible change in the discontinuous epitopes targeted by site-specific antibodies (Choudhry,
Zhang et al. 2007).

In our analysis of HIV-1 protein sequences we observed many non-

monomorphic sites with variation primarily within an amino acid chemical grouping (ex. Ile ↔
Leu) further altering possible binding epitopes. Thus the question remains as to whether HIV-1

45

mutations that confer partial resistance against RC-101 change the binding site of RC-101 or
alter its access to the binding site. Both scenarios are possible.
In attempting to evade RC-101 inhibition, HIV-1 developed three cationic mutations, one
of which removed a glycosylated residue, yet caused the virus to remain dependent on RC-101
for infectivity (Cole, Yang et al. 2006). Anionic-to-cationic mutations along the HR2 region
resulted in a normal infectious mutant only 50% of the time, with all mutants susceptible to RC101. This suggests that the negative charge on HR2 may be important for maintaining normal
replication efficiency of HIV-1, possibly by stabilizing its interaction with HR1 during 6HB
formation. Although mutations that alter the negative charge of HR2 may impair RC-101
binding, they may also have the untoward effect (for the virus) of preventing its ability to
mediate the fusion process and infect cells.
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CHAPTER FIVE: CONCLUSION
The virus’s inability to become fully resistant to RC-101 is further illustrated by an
extension of our previous work (Cole, Yang et al. 2006). Passaging the virus from round 20 to
round 28 (days 100 to 140) in the presence of 10-20 ug/ml RC-101 neither induced additional
mutations, nor increased its resistance (Figure 19). Collectively, our data indicate that it is
unlikely HIV-1 can mount further resistance to RC-101: aside from one partially resistant virus,
mutant viruses either remained infectious yet sensitive to RC-101, or suffered from a significant
loss of fusion efficiency.
The predominant problem with current HIV-1 treatments is the eventual emergence of
fully resistant mutants that are then transmitted to new hosts. The same problem is theoretically
possible for widely used topical microbicides. Our work has shown that the ability of HIV-1 to
generate escape mutants against RC-101 is limited, and thus RC-101 holds great potential as an
anti-HIV-1 microbicide in part because it remains effective against the virus.
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Figure 19 HIV-1 Remains Susceptible to RC-101 Over 28 Rounds of Infection
This figure is an extension of previous work (Cole, Yang et al. 2006). Asterisks represent rounds
where HIV was isolated from the supernatant and sequenced for mutations. Cationic mutations
in gp120 and HR1 of gp41 appeared at round 4, whereas the mutation in HR2 appeared at Round
15. The mutations remained stable throughout all successive passages.
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APPENDIX A: MANUSCRIPT SUBMISSION
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Figure 20 First Page of Submitted Manuscript to Journal of Biological Chemistry
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Figure 21 Confirmation of Primary Editoral Review
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APPENDIX B: COMPUTER PROGRAM
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All the applications developed for this thesis were written in the PHP scripting language
by Zend Technologies (www.php.net). The scripts require php language version 5 (php5). The
first two programs, DLGCLI and countBonds, are command line driven and can take advantage
of the UNIX shell or DOS command interface. DLGCLI can also be used as a webpage. The
application PrimerFind requires a webserver with php5 and may not be run as a command line
application.
Docking Log Parser Command Line Interface (DLGCLI)
Each docking experiments with AutDock 3.0 returns one computer file, a docking log
file. In summary it contains all the experimental setup variables and most importantly the
docked ligand (RC-101) molecules. DLGCLI accepts two files as input: the docking log and the
macromolecule (gp41 Heptamers). It creates a unique folder with a summary of the results and
sub-folder for each docked ligand (Figure 22).

The summary file contains information

(maximum, minimum, average, standard deviation, etc) about all the electrostatic interaction for
all the ligands produced in the experiment. The values file contains the ligands ranks according
to their final docked energy (FDE) i.e. the change in free energy upon binding.

The

Experimental Results file also contains the summary information as well as the experimental
values that went into the docking experiment. Finally, the tcsh script (TEE-SHELL script)
run_LIGPLOT will analyze the intermolecular interactions between each docked ligand and the
macromolecule. It uses the LIGPLOT and HBPLUS programs to produces a slew of result files
in each ligand folder (McDonald and Thornton 1994; Wallace, Laskowski et al. 1995). The most
important files produced by the script are the “.nnb” and “.hhb” which contain the non-hydrogen
bonds and hydrogen bonds, respectively, for that particular ligand-macromolecule pairing.
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Figure 22 File Hierarchy Produced by DLGCLI
The input files (yellow) produce a slew of data when processed by the DLGCLI application
(blue). All files are placed in a folder with the same name as the docking log. Green boxes
represent sub folders with the underlined text as the name. XXX stand for the designation of a
particular docked ligand molecule (1 to the total number of LGAs run). The teal boxes represent
the output files place in the main folder. The run_LIGPLOT script (purple) further processes the
data and produces the files in the green box on the right. It also copies the folders of the best 5
ligands to the summary folder.
CountBonds
The CountBonds application tabulates the number of interactions per macromolecule
residue and the specified upper percentile of best fit ligands. It uses the intermolecular bond data
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produced by LIGPLOT and HBPLUS (“.hhb” and “.nnb” files) and the list of docking values for
each ligand produced by DLGCLI. The application can also determine which ligand residues
and atoms play the largest role in interacting with the macromolecule. The results are in the
form of comma deliminated database that can be imported into any statistics package for further
analysis and display.
PrimerFind
The heptad repeat 2 region of gp41 is very GC poor which presents a problem when
developing primers for site-directed mutagensis. This program uses a brute force algorithm to
generate all the possible primers for a specific mutation and test each one according to the
published Stratagene Guidelines for mutagenenic primers (QuikChange Multi Site-Directed
Mutagenesis Kit). The web application, PrimerFind, accepts a DNA sequence with a desired
mutation (Figure 23) and outputs a webpage of possible primers (Figure 24). The criteria for
primers were as followed:
1. Optimal Length is 25-45 base pairs
a. Primers over 45bp may suffer from 2° structure formation
2. Melting Temperature ≥ 75°C or 78°C
a. Tm = 81.5 + .41(%GC)-675/N-%mismatch
i. N = primer length in bases
ii. %GC and %mismatch are whole numbers
b. In addition the Tm of each side should be above 55°C and as close as possible
3. Optimum GC Content ≥ 40%
4. Terminate with one or more G or C at the 3’ end
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5. The Tm of each side should be as close as possible
6. The difference in length on each side of the substitution should not exceed 5bp
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Figure 23 Input for PrimerFind
The sequence should be input as lowercase with the mutation(s) in uppercase.

Multiple

mutations should be in close proximity to each other (1-5bp). Values in the boxes represent
default values. These values are highly dependant on the reagents used in the mutagenesis
reaction and on the kit used for the experiment.
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Figure 24 Sample Output from PrimerFind
These are the results from the E to K mutation of the gp41 residue 648. The user is able to refine
their primer search without inputting the sequence over again. Also, the application outputs the
reverse compliment as a possible primer. Clicking the number on the left of a particular primer
opens a new page with summary information about that primer for ordering.
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APPENDIX C: SEQUENCE INFORMATION
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A large amount of HIV sequence information has been published at the HIV Sequence
Database at the Los Alamos National Laboratories (LANL; www.hiv.lanl.gov). The following
two pages summarize the information garnered from the HR1 and HR2 regions of the Group M
viruses in the database.

Each row represents a location on the amino acid sequence. The

numbering of HR1 and HR2 are based off of the uncleaved gp160 protein of the HXB2 standard
strain. Cell in red represent an amino acid that is observed more than 50% of the time. Yellow
cells represent an amino acid observed between 100 and 50% of the time in the database. And
green cells represent amino acids seen between 1 and 99 times in the database. Amino acid
diversity values in red represent values less than .05.
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Figure 25 HR1 Sequence Information
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Figure 26 HR2 Sequence Information
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